Literature DB >> 14630268

Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters.

Hoon K Lee1, Ara A Vaporciyan, James D Cox, Susan L Tucker, Joe B Putnam, Jaffer A Ajani, Zhongxing Liao, Stephen G Swisher, Jack A Roth, W Roy Smythe, Garrett L Walsh, Radhe Mohan, Hui H Liu, Deidre Mooring, Ritsuko Komaki.   

Abstract

PURPOSE: To clarify the relationship between the percentage of lung receiving low radiation doses with concurrent chemotherapy and the occurrence of postoperative pulmonary complications in the treatment of esophageal carcinoma.
METHODS: From 117 patients who underwent preoperative chemoradiation for esophageal cancer at our institution between 1998 and 2002, we selected 61 patients for whom complete pulmonary dose-volume histogram (DVH) data were available and analyzed the incidence of pneumonia and acute respiratory distress syndrome (ARDS) in this group. All patients received concurrent chemoradiation therapy, and 39 patients also received induction chemotherapy before concurrent chemoradiation. The median age was 62 years, and the median radiotherapy dose was 45 Gy. The percentage of lung volume receiving at least 10 Gy (V10), 15 Gy (V15), and 20 Gy (V20) were recorded from each pulmonary DVH.
RESULTS: Eleven (18%) of the 61 patients had pulmonary complications, 2 of whom died after progression of pneumonia. Pulmonary complications were noted more often (35% vs. 8%, p = 0.014) when the pulmonary V10 was > or =40% vs. <40% and when the V15 was > or /=30% vs. < 30% (33% vs. 10%, p = 0.036). An apparent increase in pulmonary complication rate when V20 was > or =20% vs. <20% (32% vs. 10%, p = 0.079) was not significant. None of the other factors analyzed (surgical procedure, tumor location, use of induction chemotherapy, use of concurrent taxane-based chemoradiation, or smoking history) was associated with the occurrence of pulmonary complications. The median hospital stay was 17 days for patients who had pulmonary complications vs. 12 days for patients who did not (p = 0.08).
CONCLUSIONS: The use of multimodality therapy may require minimization of lung volume irradiation to levels lower than previously expected. Radiotherapy techniques that decrease the volume of lung receiving low radiation doses may significantly reduce the risk of this potentially life-threatening complication.

Entities:  

Mesh:

Year:  2003        PMID: 14630268     DOI: 10.1016/s0360-3016(03)01373-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  38 in total

1.  Analysis of dose-volume parameters predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-conformal radiation therapy or IMRT.

Authors:  Gaurav Kumar; Sheh Rawat; Abhishek Puri; Manoj Kumar Sharma; Pranav Chadha; Anand Giri Babu; Girigesh Yadav
Journal:  Jpn J Radiol       Date:  2011-12-14       Impact factor: 2.374

2.  Helical tomotherapy for radiochemotherapy in esophageal cancer: a preferred plan?

Authors:  Gary Y Yang
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

3.  Simultaneous irradiation of the breast and regional lymph nodes in prone position using helical tomotherapy.

Authors:  K Kainz; J White; G-P Chen; J Hermand; M England; X A Li
Journal:  Br J Radiol       Date:  2012-03-28       Impact factor: 3.039

4.  Spanish radiobiological pattern of care in lung cancer: a GOECP/SEOR study.

Authors:  J A González; M Chust; R Delgado; A Gómez; N Rodríguez; M J Ruiz; F Casas
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

Review 5.  Technological advances in radiotherapy for esophageal cancer.

Authors:  Milan Vosmik; Jiri Petera; Igor Sirak; Miroslav Hodek; Petr Paluska; Jiri Dolezal; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

Review 6.  Strategies to reduce pulmonary complications after esophagectomy.

Authors:  Teus J Weijs; Jelle P Ruurda; Grard A P Nieuwenhuijzen; Richard van Hillegersberg; Misha D P Luyer
Journal:  World J Gastroenterol       Date:  2013-10-21       Impact factor: 5.742

7.  Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer.

Authors:  Arya Amini; Katherine Ciura; James Welsh; Ngoc Nguyen; Matt Palmer; Pamela K Allen; Michael Paolini; Zhongxing Liao; Jaques Bluett; Radhe Mohan; Daniel Gomez; James D Cox; Ritsuko Komaki; Joe Y Chang
Journal:  Med Dosim       Date:  2013       Impact factor: 1.482

8.  Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients.

Authors:  Stefania Martini; Francesca Arcadipane; Paolo Strignano; Rosella Spadi; Viviana Contu; Christian Fiandra; Riccardo Ragona; Giorgia Catalano; Maria Antonietta Satolli; Michele Camandona; Renato Romagnoli; Umberto Ricardi; Pierfrancesco Franco
Journal:  Med Oncol       Date:  2018-10-04       Impact factor: 3.064

9.  Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma.

Authors:  K Fakhrian; M Oechsner; S Kampfer; T Schuster; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

10.  Neoadjuvant hyperfractionated-accelerated radiotherapy with concomitant chemotherapy in esophageal cancer: phase II study.

Authors:  Sezer Saglam; Alptekin Arifoglu; Esra Kaytan Saglam; Fatih Tunca; Oktar Asoglu; Gulgun Engin; Sumer Yamaner
Journal:  J Gastrointest Oncol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.